Literature DB >> 14509884

A systematic review of outcome following synchronous carotid endarterectomy and coronary artery bypass: influence of surgical and patient variables.

R Naylor1, R L Cuffe, P M Rothwell, I M Loftus, P R Bell.   

Abstract

OBJECTIVES: Outcomes after synchronous carotid endarterectomy (CEA) plus coronary artery bypass (CABG) relative to surgical and patient based variables.
DESIGN: Systematic review of 94 published series (7863 synchronous procedures).
RESULTS: 11.5% of patients died or suffered a stroke/myocardial infarction in the peri-operative period (95% CI 10.1-12.9). The risk of death/stroke appeared to significantly diminish in studies published between 1993-2002, compared with 1972-1992 (7.2% (95% CI 6.5-9.1) versus 10.7% (95% CI 8.9-12.5), p = 0.03). However, increasing operative experience was not associated with significantly lower risks of death/stroke; (1-49 cases (9.6% (95% CI 7.5-11.8); 50-99 cases (9.1% (95% CI 6.4-11.8); 100+ cases (8.4% (95% CI 6.9-10.1) (p = 0.64)). Patients with severe bilateral carotid disease were significantly more likely to suffer death and/or stroke compared to patients with unilateral disease (odds ratio 2.5, 95% CI 1.4-5.0, p = 0.001). Similarly, patients with a prior history of stroke/transient ischaemic attack (TIA) were significantly more likely to suffer a further stroke than asymptomatic patients (odds ratio 1.8, 95% CI 1.1-2.8, p = 0.008). There was no difference in the risk of death/stroke relative to the timing of CEA (pre- versus on-cardiopulmonary bypass), but recent small studies indicate that improved outcomes might be achieved by performing CABG 'off-bypass'.
CONCLUSIONS: Synchronous CEA + CABG is associated with a not insignificant cardiovascular risk. No comparable information is available for similar patients undergoing CABG without prophylactic CEA.

Entities:  

Mesh:

Year:  2003        PMID: 14509884     DOI: 10.1053/ejvs.2002.1975

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  7 in total

1.  Multisystem revascularization.

Authors:  Zehra Jaffery; Arthur Grant
Journal:  Ochsner J       Date:  2009

2.  Staged carotid endarterectomy under local anaesthetic in patients requiring cardiac surgery.

Authors:  David Birchley; Jaime Villaquiran; Enoch Akowuah; Terence Lewis; Simon Ashley
Journal:  Ann R Coll Surg Engl       Date:  2010-04-09       Impact factor: 1.891

Review 3.  Contemporary Management of Patients with Concomitant Coronary and Carotid Artery Disease.

Authors:  Mun J Poi; Angela Echeverria; Peter H Lin
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

4.  Carotid intervention 1: who should be treated?

Authors:  Trevor Cleveland
Journal:  Semin Intervent Radiol       Date:  2007-06       Impact factor: 1.513

5.  Interactions between cardiovascular and cerebrovascular disease.

Authors:  Giuseppe Di Pasquale; Stefano Urbinati; Enrica Perugini; Simona Gambetti
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

6.  The role of combined carotid endarterectomy and coronary artery bypass grafting in the era of carotid stenting in view of long-term results.

Authors:  Eli Levy; Dimtry Yakubovitch; Ehud Rudis; Haim Anner; Giora Landsberg; Yaakov Berlatzky; Amir Elami
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-11

7.  Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting: A Randomized Clinical Trial.

Authors:  Christian Weimar; Konstantinos Bilbilis; Jan Rekowski; Torulv Holst; Friedhelm Beyersdorf; Martin Breuer; Manfred Dahm; Anno Diegeler; Arne Kowalski; Sven Martens; Friedrich W Mohr; Jiri Ondrášek; Beate Reiter; Peter Roth; Ralf Seipelt; Markus Siggelkow; Gustav Steinhoff; Anton Moritz; Mathias Wilhelmi; Gerhard Wimmer-Greinecker; Hans-Christoph Diener; Heinz Jakob; Claudia Ose; Andre Scherag; Stephan C Knipp
Journal:  Stroke       Date:  2017-09-15       Impact factor: 7.914

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.